 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Molecular diagnostic company Seegene's operating loss in the third quarter on a consolidated basis was KRW 10.1 billion, down sharply from a year earlier.
On the 10th, Seegene announced in a tentative announcement that its consolidated operating loss in the third quarter of this year was 10.1 billion won, up 68.7% from a year earlier.
Sales fell 39.1 percent to 91.9 billion won during the same period. Net loss was 4.7 billion won, up 58.5% from the same period last year (11.3 billion won).
The Seegene said sales of related products declined following the COVID-19's transition to the endgame, which led to a drop in sales.
The company explained that operating losses last year occurred in the process of handling the loss of Corona-related stocks, and that losses in the third quarter of this year occurred due to preparation for new businesses and research and development (R＆D) costs.
In the third quarter of this year, product sales reached 57.9 billion won, up 36% from the same period last year.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
